Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 96

1.
2.

Gene panel testing for inherited cancer risk.

Hall MJ, Forman AD, Pilarski R, Wiesner G, Giri VN.

J Natl Compr Canc Netw. 2014 Sep;12(9):1339-46. Review.

PMID:
25190699
3.

An Objective Method for Evaluating Next-Generation Sequencing Panels.

Angione K, Gibbons M, Demarest S.

J Child Neurol. 2018 Dec 20:883073818815036. doi: 10.1177/0883073818815036. [Epub ahead of print]

PMID:
30569809
4.

The integration of next-generation sequencing panels in the clinical cancer genetics practice: an institutional experience.

Mauer CB, Pirzadeh-Miller SM, Robinson LD, Euhus DM.

Genet Med. 2014 May;16(5):407-12. doi: 10.1038/gim.2013.160. Epub 2013 Oct 10.

PMID:
24113346
5.

An update on genetic risk assessment and prevention: the role of genetic testing panels in breast cancer.

Piccinin C, Panchal S, Watkins N, Kim RH.

Expert Rev Anticancer Ther. 2019 Sep;19(9):787-801. doi: 10.1080/14737140.2019.1659730. Epub 2019 Sep 7.

PMID:
31469018
6.

Rescreening for genetic mutations using multi-gene panel testing in patients who previously underwent non-informative genetic screening.

Frey MK, Kim SH, Bassett RY, Martineau J, Dalton E, Chern JY, Blank SV.

Gynecol Oncol. 2015 Nov;139(2):211-5. doi: 10.1016/j.ygyno.2015.08.006. Epub 2015 Aug 18.

PMID:
26296696
7.

Evaluation of laboratory perspectives on hereditary cancer panels.

Stoll J, Weissman SM, Hook N, Selkirk C, Johnson AK, Newlin A, Vogel Postula KJ.

Fam Cancer. 2016 Oct;15(4):689-96. doi: 10.1007/s10689-016-9880-x.

PMID:
26869169
8.

Cancer risk assessment using genetic panel testing: considerations for clinical application.

Hiraki S, Rinella ES, Schnabel F, Oratz R, Ostrer H.

J Genet Couns. 2014 Aug;23(4):604-17. doi: 10.1007/s10897-014-9695-6. Epub 2014 Mar 7.

PMID:
24599651
9.
10.

Development and Validation of Targeted Next-Generation Sequencing Panels for Detection of Germline Variants in Inherited Diseases.

Santani A, Murrell J, Funke B, Yu Z, Hegde M, Mao R, Ferreira-Gonzalez A, Voelkerding KV, Weck KE.

Arch Pathol Lab Med. 2017 Jun;141(6):787-797. doi: 10.5858/arpa.2016-0517-RA. Epub 2017 Mar 21.

PMID:
28322587
11.

The evolution of cancer risk assessment in the era of next generation sequencing.

Fecteau H, Vogel KJ, Hanson K, Morrill-Cornelius S.

J Genet Couns. 2014 Aug;23(4):633-9. doi: 10.1007/s10897-014-9714-7. Epub 2014 Apr 24.

PMID:
24756768
12.

Genetic testing for hereditary prostate cancer: Current status and limitations.

Zhen JT, Syed J, Nguyen KA, Leapman MS, Agarwal N, Brierley K, Llor X, Hofstatter E, Shuch B.

Cancer. 2018 Aug 1;124(15):3105-3117. doi: 10.1002/cncr.31316. Epub 2018 Apr 18. Review.

13.

The impact of hereditary cancer gene panels on clinical care and lessons learned.

Okur V, Chung WK.

Cold Spring Harb Mol Case Stud. 2017 Nov 21;3(6). pii: a002154. doi: 10.1101/mcs.a002154. Print 2017 Nov.

14.

Collaboration of colorado cancer genetic counselors to integrate next generation sequencing panels into clinical practice.

Wolfe Schneider K, Anguiano A, Axell L, Barth C, Crow K, Gilstrap M, Hamlington BA, Lesh S, Mullineaux L, Rahm AK, Strait E, Freivogel M.

J Genet Couns. 2014 Aug;23(4):640-6. doi: 10.1007/s10897-014-9718-3. Epub 2014 May 1.

PMID:
24781714
15.

A closer look at expanded carrier screening from a PGD perspective.

Vaz-de-Macedo C, Harper J.

Hum Reprod. 2017 Oct 1;32(10):1951-1956. doi: 10.1093/humrep/dex272.

PMID:
28938745
16.

Benchmarking of Whole Exome Sequencing and Ad Hoc Designed Panels for Genetic Testing of Hereditary Cancer.

Feliubadaló L, Tonda R, Gausachs M, Trotta JR, Castellanos E, López-Doriga A, Teulé À, Tornero E, Del Valle J, Gel B, Gut M, Pineda M, González S, Menéndez M, Navarro M, Capellá G, Gut I, Serra E, Brunet J, Beltran S, Lázaro C.

Sci Rep. 2017 Jan 4;7:37984. doi: 10.1038/srep37984.

17.

Implementation and utilization of genetic testing in personalized medicine.

Abul-Husn NS, Owusu Obeng A, Sanderson SC, Gottesman O, Scott SA.

Pharmgenomics Pers Med. 2014 Aug 13;7:227-40. doi: 10.2147/PGPM.S48887. eCollection 2014. Review.

18.

The Clinical Utility of Next Generation Sequencing Results in a Community-Based Hereditary Cancer Risk Program.

Bunnell AE, Garby CA, Pearson EJ, Walker SA, Panos LE, Blum JL.

J Genet Couns. 2017 Feb;26(1):105-112. doi: 10.1007/s10897-016-9985-2. Epub 2016 Jun 9.

PMID:
27276934
19.

Monitoring Melanoma Using Circulating Free DNA.

Diefenbach RJ, Lee JH, Rizos H.

Am J Clin Dermatol. 2019 Feb;20(1):1-12. doi: 10.1007/s40257-018-0398-x. Review.

PMID:
30374893
20.

Exome sequencing covers >98% of mutations identified on targeted next generation sequencing panels.

LaDuca H, Farwell KD, Vuong H, Lu HM, Mu W, Shahmirzadi L, Tang S, Chen J, Bhide S, Chao EC.

PLoS One. 2017 Feb 2;12(2):e0170843. doi: 10.1371/journal.pone.0170843. eCollection 2017.

Supplemental Content

Support Center